The American Journal of Medicine
Volume 120, Issue 8 , Pages 706-712 , August 2007

Impact of Statin Dosing Intensity on Transaminase and Creatine Kinase

  • Krista M. Dale, PharmD

      Affiliations

    • The University of Connecticut Schools of Pharmacy, Hartford, Conn.
    • Storrs and Farmington; and the Divisions of Cardiology, Hartford, Conn.
    • Drug Information, Hartford Hospital, Hartford, Conn.
    • ,
  • C. Michael White, PharmD

      Affiliations

    • The University of Connecticut Schools of Pharmacy, Hartford, Conn.
    • Storrs and Farmington; and the Divisions of Cardiology, Hartford, Conn.
    • Drug Information, Hartford Hospital, Hartford, Conn.
    • ,
  • Nickole N. Henyan, PharmD

      Affiliations

    • The University of Connecticut Schools of Pharmacy, Hartford, Conn.
    • Storrs and Farmington; and the Divisions of Cardiology, Hartford, Conn.
    • Drug Information, Hartford Hospital, Hartford, Conn.
    • ,
  • Jeffrey Kluger, MD

      Affiliations

    • The University of Connecticut Schools of Medicine, Hartford, Conn.
    • Storrs and Farmington; and the Divisions of Cardiology, Hartford, Conn.
    • ,
  • Craig I. Coleman, PharmD

      Affiliations

    • The University of Connecticut Schools of Pharmacy, Hartford, Conn.
    • Storrs and Farmington; and the Divisions of Cardiology, Hartford, Conn.
    • Drug Information, Hartford Hospital, Hartford, Conn.
    • Corresponding Author InformationRequests for reprints should be addressed to Craig I. Coleman, PharmD, Assistant Professor of Pharmacy, University of Connecticut, and Director, Pharmacoeconomics and Outcomes Studies Group, Hartford Hospital, Hartford, CT 06102-5037.

References 

  1. Cannon CP, Braunwald E, McCave Ch, et al. Intensive versus moderate lipid lowering with statin after acute coronary syndromes. N Engl J Med. 2004;350:1495–1504
  2. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Eng J Med. 2005;352:1425–1435
  3. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clin Trials. 1986;7:177–188
  4. Naylor AF. Small sample considerations in combining 2×2 tables. Biometrics. 1967;23:349–356
  5. Jadad AR, DPhil R, Moore A, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clin Trials. 1996;17:1–12
  6. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1957;22:719–748
  7. deLemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z Trial. JAMA. 2004;292:1307–1316
  8. Taylor AJ, Kent SM, Flaherty PJ, et al. ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation. 2002;206:2055–2060
  9. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004;291:1071–1080
  10. Raggi P, Davidson M, Callister TQ, et al. Aggressive versus moderate lipid-lowering therapy in hypercholesterolemic postmenopausal women: beyond endorsed lipid lowering with EBT scanning (BELLES). Circulation. 2005;112:563–571
  11. Post-CABG: The Post Coronary Artery Bypass Graft Trial Investigators. the effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary artery bypass grafts. N Engl J Med. 1997;336:153–162
  12. Smilde TJ, van Wissen S, Wollersheim H, et al. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomized, double-blinded, trial. Lancet. 2001;357:577–581
  13. Pedersen TR, Faergeman O, Kastelein JJP, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction, the IDEAL Study: a randomized controlled trial. JAMA. 2005;294:2437–2445
  14. Tamai I, Nezu J, Uchino H, et al. Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun. 2000;273:251–260
  15. McTavish D, Sorkin EM. Pravastatin: a review of its pharmacologic properties and therapeutic potential in hypercholesterolemia. Drugs. 1991;42:65–89
  16. Negre-Aminou P, Van Vliet AK, Van Erck M, et al. Inhibition of proliferation of human smooth muscle cells by various HMG CoA reductase inhibitors: comparison with other human cell types. Biochemica et Biophysica Acta. 1997;1345:259–268
  17. Newman C, Szarek M, Luo D, et al. Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients. Am J Cardiol. 2006;97:61–67
  18. White CM. A review of pharmacologic and pharmacokinetic aspects of rosuvastatin. J Clin Pharmacol. 2002;42:963–970
  19. White CM, Chow MSS. A review of HMG CoA reductase inhibitors. US Pharmacist. 1998;23:H19–HS30
  20. Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med. 2002;346:539–540

PII: S0002-9343(06)01021-7

doi: 10.1016/j.amjmed.2006.07.033

The American Journal of Medicine
Volume 120, Issue 8 , Pages 706-712 , August 2007

Article Tools

* Image Usage & Resolution